Paclitaxel pharmacokinetics and pharmacodynamics.
Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) displays nonlinear pharmacokinetics in humans. Both peak plasma paclitaxel concentrations and areas under the curve (AUCs) of the concentration versus time profiles will change disproportionately to changes in dose. Models that accurately describe the plasma paclitaxel profile contain two separate saturable processes, both described by Michaelis-Menten kinetics. Pharmacokinetic models using only linear components ultimately fail to describe adequately the disposition of paclitaxel in the body. The major toxicity of paclitaxel, neutropenia, appears to be related to the duration of time that plasma paclitaxel concentrations are at or above a threshold value. This relationship is well described by a sigmoid-Emax (maximum effect) model. Neutropenia is not directly related to either peak paclitaxel plasma concentration or to paclitaxel areas under the curve. A relationship between therapeutic efficacy and paclitaxel disposition is, as yet, undefined.
Kearns
C M
CM
Division of Developmental Therapeutics, University of Maryland Cancer Center, Baltimore 21201, USA.
Gianni
L
L
Egorin
M J
MJ
D002986:Clinical Trials as Topic; D006801:Humans; D016014:Linear Models; D008954:Models, Biological; D009369:Neoplasms / Q000188:drug therapy; D017239:Paclitaxel / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000494:pharmacology
D017239:Paclitaxel